LinkedIn Profile

Access Trevi Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:trevitherapeutics 2073467 Dec 3rd, 2020 12:00AM Trevi Therapeutics, Inc. 834 25.00 Open Biotechnology Dec 3rd, 2020 03:05PM Dec 3rd, 2020 03:05PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Dec 2nd, 2020 12:00AM Trevi Therapeutics, Inc. 834 25.00 Open Biotechnology Dec 2nd, 2020 04:53PM Dec 2nd, 2020 04:53PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Dec 1st, 2020 12:00AM Trevi Therapeutics, Inc. 834 25.00 Open Biotechnology Dec 1st, 2020 03:25PM Dec 1st, 2020 03:25PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Nov 30th, 2020 12:00AM Trevi Therapeutics, Inc. 832 25.00 Open Biotechnology Nov 29th, 2020 09:24PM Nov 30th, 2020 04:12PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Nov 28th, 2020 12:00AM Trevi Therapeutics, Inc. 832 25.00 Open Biotechnology Nov 28th, 2020 04:58PM Nov 28th, 2020 04:58PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Nov 27th, 2020 12:00AM Trevi Therapeutics, Inc. 830 25.00 Open Biotechnology Nov 27th, 2020 01:24PM Nov 27th, 2020 01:24PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Nov 26th, 2020 12:00AM Trevi Therapeutics, Inc. 830 25.00 Open Biotechnology Nov 25th, 2020 08:25PM Nov 25th, 2020 08:25PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Nov 24th, 2020 12:00AM Trevi Therapeutics, Inc. 830 25.00 Open Biotechnology Nov 24th, 2020 03:58PM Nov 24th, 2020 03:58PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Nov 23rd, 2020 12:00AM Trevi Therapeutics, Inc. 828 25.00 Open Biotechnology Nov 23rd, 2020 05:47PM Nov 23rd, 2020 05:47PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services
private:trevitherapeutics 2073467 Nov 22nd, 2020 12:00AM Trevi Therapeutics, Inc. 828 24.00 Open Biotechnology Nov 22nd, 2020 04:43PM Nov 22nd, 2020 04:43PM Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Founded in 2011, Trevi is headquartered in New Haven, CT. Open Open 195 Church Street, 14th Floor New Haven CT US 06510 Trevi Therapeutics Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.